Oppenheimer & Co. Inc. Decreases Position in Pfizer Inc. (PFE)

Oppenheimer & Co. Inc. lessened its holdings in shares of Pfizer Inc. (NYSE:PFE) by 2.0% during the 4th quarter, HoldingsChannel.com reports. The firm owned 767,889 shares of the biopharmaceutical company’s stock after selling 15,445 shares during the period. Pfizer comprises about 1.0% of Oppenheimer & Co. Inc.’s portfolio, making the stock its 7th biggest holding. Oppenheimer & Co. Inc.’s holdings in Pfizer were worth $33,519,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. First Command Financial Services Inc. increased its holdings in shares of Pfizer by 8.4% during the 3rd quarter. First Command Financial Services Inc. now owns 31,470 shares of the biopharmaceutical company’s stock worth $1,386,000 after purchasing an additional 2,448 shares during the period. Steward Partners Investment Advisory LLC increased its holdings in shares of Pfizer by 19.2% during the 3rd quarter. Steward Partners Investment Advisory LLC now owns 340,182 shares of the biopharmaceutical company’s stock worth $14,992,000 after purchasing an additional 54,857 shares during the period. Geneva Partners LLC bought a new position in shares of Pfizer during the 3rd quarter worth about $483,000. Accredited Investors Inc. increased its holdings in shares of Pfizer by 9.9% during the 3rd quarter. Accredited Investors Inc. now owns 26,310 shares of the biopharmaceutical company’s stock worth $1,160,000 after purchasing an additional 2,369 shares during the period. Finally, Fisher Asset Management LLC increased its holdings in shares of Pfizer by 2.6% during the 3rd quarter. Fisher Asset Management LLC now owns 40,477,731 shares of the biopharmaceutical company’s stock worth $1,783,854,000 after purchasing an additional 1,032,614 shares during the period. 69.36% of the stock is currently owned by institutional investors and hedge funds.

Several research analysts have recently issued reports on the stock. Argus upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $55.00 price objective on the stock in a report on Thursday, January 31st. Zacks Investment Research downgraded shares of Pfizer from a “hold” rating to a “sell” rating in a report on Friday, January 25th. Credit Suisse Group reiterated a “buy” rating and set a $48.00 target price on shares of Pfizer in a research report on Monday. Bank of America lifted their target price on shares of Pfizer from $45.00 to $48.00 and gave the company a “buy” rating in a research report on Monday, April 1st. Finally, JPMorgan Chase & Co. reiterated a “neutral” rating and set a $46.00 target price on shares of Pfizer in a research report on Friday, April 19th. Fourteen equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $45.78.

In other Pfizer news, insider Mikael Dolsten sold 100,471 shares of the business’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $43.56, for a total value of $4,376,516.76. Following the transaction, the insider now directly owns 390,097 shares in the company, valued at $16,992,625.32. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Alexander R. Mackenzie sold 15,000 shares of the business’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $42.83, for a total transaction of $642,450.00. Following the completion of the transaction, the insider now owns 124,994 shares in the company, valued at $5,353,493.02. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 288,726 shares of company stock worth $12,534,617. Company insiders own 0.09% of the company’s stock.

Shares of Pfizer stock opened at $40.83 on Wednesday. The company has a current ratio of 1.57, a quick ratio of 1.33 and a debt-to-equity ratio of 0.52. Pfizer Inc. has a twelve month low of $34.71 and a twelve month high of $46.47. The stock has a market cap of $246.39 billion, a PE ratio of 13.61, a price-to-earnings-growth ratio of 2.40 and a beta of 0.71.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, April 30th. The biopharmaceutical company reported $0.85 earnings per share for the quarter, beating the consensus estimate of $0.75 by $0.10. The business had revenue of $13.12 billion for the quarter, compared to analyst estimates of $13.01 billion. Pfizer had a net margin of 21.31% and a return on equity of 26.54%. The firm’s revenue was up 1.6% on a year-over-year basis. During the same period in the previous year, the business earned $0.77 EPS. Research analysts forecast that Pfizer Inc. will post 2.89 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, June 7th. Shareholders of record on Friday, May 10th will be given a $0.36 dividend. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.44 dividend on an annualized basis and a yield of 3.53%. Pfizer’s dividend payout ratio (DPR) is presently 48.00%.

TRADEMARK VIOLATION NOTICE: “Oppenheimer & Co. Inc. Decreases Position in Pfizer Inc. (PFE)” was posted by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this news story can be accessed at https://www.baseballdailydigest.com/news/2019/05/08/oppenheimer-co-inc-decreases-position-in-pfizer-inc-pfe.html.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

See Also: Real Estate Investment Trust (REIT) ETF

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.